PharmaMar , Almirall , Faes , Rovi ... Why the Spanish Pharmaceutical Sector Could Take Over the Ibex 35 .

The Spanish Pharmaceutical Sector is likely to continue to Grow over the course of 2020 and we should Expect to see more of them Take a Place on the Ibex35.

Published by Isaac Atwood in Biotech , Featured , Top Stories.

The Spanish Pharmaceutical Sector has Performed strongly over the course of last year. For example Pharmamar, has boosted its capitalization by 227% to almost $890 million (€800 million). The strong performance of many companies in the sector has led to a number requesting a place on the Ibex 35.

One of these companies is Almirall. The Catalan company already has a market cap of more than $2,839 million (€2,550 million), while another candidate Faes Farma, is worth about 1,400 million after rising almost 75%.

Get the latest biotechnology news at your fingertips. Discover what is new in biotech research, finance, business, and more with Born2Invest. Our companion app includes news updates of finance headlines from fin-tech for investing and cannabis.

To understand why Pharmaceutical companies are becoming so important for the Spanish economy it makes sense to break down their performance on an individual basis. ...

PharmaMar 

The Sector’s Leading Player was Undoubtedly PharmaMar. The former Zeltia, has experienced nothing but advances throughout 2019 ever since the U.S. Drug Enforcement Agency approved the registration of its new lurbinectedine drug for the treatment of small-cell lung cancer on an accelerated basis.

In addition, the company has reached an agreement with Janssen to sell Yondelis (chemotherapy treatment) in 40 countries, and the icing on the cake was received in December when he signed an exclusive agreement with Jazz Pharmaceuticals to sell their star drug, lurbinectedin, in the U. S., which could bring in up to $900 million, taking into account certain variables.